Pfizer Strikes $6B+ Oncology Deal with 3SBio for Global Rights to Promising Bispecific Antibody SSGJ-707

New York, May 19, 2025 (Business Wire) -- Pfizer has entered into a global (ex-China) licensing agreement with 3SBio for SSGJ-707, a promising bispecific antibody in clinical trials for multiple cancers. The deal includes a $1.25 billion upfront payment, up to $4.8 billion in potential milestone payments, and double-digit tiered royalties. Pfizer will also invest $100 million in 3SBio and handle global manufacturing outside China.

Read full article here.